Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy

Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy

Background and PurposeWe investigated the locoregional effect of trastuzumab, and determined whether patients with human epidermal growth factor receptor (HER)2-positive breast cancer (BC) treated with trastuzumab could achieve comparable efficacy to that of patients with HER2-negative BC.Materials...

Full description

Bibliographic Details
Main Authors: Guang-Yi Sun, Hao Jing, Shu-Lian Wang, Yong-Wen Song, Jing Jin, Hui Fang, Yue-Ping Liu, Hua Ren, Yu Tang, Xu-Ran Zhao, Yu-Chun Song, Si-Ye Chen, Zhuan-Bo Yang, Bo Chen, Yuan Tang, Ning Li, Ning-Ning Lu, Shu-Nan Qi, Yong Yang, Ye-Xiong Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Oncology
Subjects:
breast cancer
HER2
trastuzumab
radiotherapy
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.605750/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.605750/full

Similar Items